Angioimmunoblastic T cell lymphoma
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
Angioimmunoblastic T-cell lymphoma (AITL) (previously known as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD)) is a rare, aggressive (fast-growing) form of peripheral T-cell lymphoma. It only accounts for around 1-2% of all non-Hodgkin lymphoma. It is one of the more common subtypes of mature T-cell lymphomas.
It is more common in the elderly.
The clinical spectrum includes:
Treatment and prognosis
Despite advances in treatment regimens for angioimmunoblastic T cell lymphoma, prognosis remains poor with an overall 5-year median survival of 32% 3.
History and etymology
It was initially described in 1974 by Frizzera et al as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD).
- 1. Rodríguez J, Conde E, Gutiérrez A et-al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur. J. Haematol. 2007;78 (4): 290-6. doi:10.1111/j.1600-0609.2007.00815.x - Pubmed citation
- 2. Lee HJ, Im JG, Goo JM et-al. Peripheral T-cell lymphoma: spectrum of imaging findings with clinical and pathologic features. Radiographics. 2003;23 (1): 7-26. doi:10.1148/rg.231025018 - Pubmed citation
- 3. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 129 (9): 1095-1102. doi:10.1182/blood-2016-09-692541 - Pubmed
- 4. Limpert J, Limpert MH, Limpert VD, Limpert. Angioimmunoblastic lymphadenopathy: clinical and radiological features. (1984) Radiology. doi:10.1148/radiology.152.1.6729133 - Pubmed